LONDON–(BUSINESS WIRE)– #GlobalPlanoSunglassesMarket–The plano sunglasses market will grow by USD 4.52 billion during 2020-2024, according to Technavio
Category: Business
Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study
DUBLIN & CAMBRIDGE, United Kingdom & BRISBANE, Australia–(BUSINESS WIRE)–Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces the successful completion of a P…
Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society Meeting
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retina diseases, announced today that i…
STAAR Surgical Reports Fourth Quarter and Full Year 2019 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fi…
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Si…
Alcon Reports Full Year 2019 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Full Year 2019 Results
Outlook into the Global Optical Measurement Market to 2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Optical Measurement Market Analysis & Trends – Industry Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. The Global Optical Measurement Market is poised to grow strong during the for…
Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced that Elisab…
Tej Kohli Foundation will neue Projekte ausarbeiten, die Hornhautblindheit bis 2035 beseitigen können
LONDON–(BUSINESS WIRE)–Die Tej Kohli Foundation will einen neuen Inkubator einrichten, um Projekte mit dem Potenzial, weltweit zur Beseitigung von Hornhautblindheit beizutragen, mit Start- und Beschleunigungsfinanzierung zu unterstützen. Finanzmittel…
La Fondation Tej Kohli cherche à incuber de nouveaux projets susceptibles d'éliminer la cécité cornéenne d'ici 2035
LONDRES–(BUSINESS WIRE)–La Fondation Tej Kohli va créer un nouvel incubateur pour fournir des fonds de démarrage et d’accélération à des projets susceptibles de contribuer à l’élimination de la cécité cornéenne dans le monde entier. Des financements,…
La Fundación Tej Kohli busca incentivar nuevos proyectos que permitan eliminar la ceguera corneal para el año 2035
LONDRES–(BUSINESS WIRE)–La Fundación Tej Kohli va a fundar un nuevo centro incubador para proporcionar financiación inicial y de aceleración a proyectos con el potencial de ayudar a eliminar la ceguera corneal en todo el mundo. La financiación, los r…
Polarized Sunglasses Market 2019-2023 | Rising Product Premiumization Due to Increased Innovation and Portfolio Extension to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalPolarizedSunglassesMarket–The polarized sunglasses market is poised to grow by USD 1.77 bn during 2019-2023
Riassunto: La Tej Kohli Foundation punta a incorporare nuovi progetti che potrebbero eradicare la cecità corneale entro il 2035
LONDRA–(BUSINESS WIRE)–La Tej Kohli Foundation formerà un nuovo incubatore per offrire finanziamenti di avviamento e velocizzazione ai progetti dotati del potenziale per eliminare globalmente la cecità corneale. Il testo originale del presente annunc…
Tej Kohli Foundation Seeks to Incubate New Projects That Can Eliminate Corneal Blindness By 2035
LONDON–(BUSINESS WIRE)–The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capit…
Global Artificial Eye Market 2019-2023 | Evolving Opportunities with Advanced Artificial Eyes and Erickson Laboratories | Technavio
LONDON–(BUSINESS WIRE)– #ArtificialEyeMarketGrowth–The global artificial eye market is poised to grow by USD 24.6 million during 2019-2023
IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020.
Resumen: RIBOMIC anuncia la primera inyección en el ensayo clínico de fase 2 de RMB-007 (estudio TOFU) en sujetos que sufren degeneración macular húmeda asociada con la edad
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc., empresa farmacéutica de etapa clínica especializada en terapias con aptámeros y que cotiza en el mercado de Empresas Madres de la Bolsa de Tokio (Número de código: 4591), ha anunciado hoy que se le ha administrado…
RIBOMIC annonce la première injection dans l’essai clinique de phase 2 portant sur le RBM-007 (Étude TOFU) chez des sujets atteints de dégénérescence maculaire liée à l’âge, dans sa forme humide
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., une société pharmaceutique de stade clinique, spécialisée dans les produits thérapeutiques à base d’aptamères, et cotée au Mothers Market de la Bourse de Tokyo (numéro de code : 4591), a annoncé aujourd’hui qu’un …
RIBOMIC kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc. ist ein auf Aptamer-Therapeutika spezialisiertes Pharmaunternehmen im klinischen Segment und wird am Mothers Market der Tokioter Börse gehandelt (Codenummer: 4591). Das Unternehmen gab heute bekannt, dass der erste…